Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.

Takeshita Y, Kita Y, Tanaka T, Goto H, Nakano Y, Teramura C, Enyama Y, Takamura T

Journal of diabetes investigation8 Feb 2022Cited by 4 (Europe PMC)

PMID35034428PMCIDPMC9153847DOI10.1111/jdi.13749PepBankPUB-35034428

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

2 results from studies that gave the peptide. 2 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with poorly controlled type 2 diabetes, liraglutide given first lowered fasting plasma glucose significantly by week 24.
In plain wordsIn adults with poorly controlled type 2 diabetes, liraglutide lowered fasting blood glucose by week 24.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose change by week 24 (liraglutide first group)
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.9 mg · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
The levels of fasting plasma glucose and HbA1c significantly decreased in the Insulin-GLP-1 RA relay group (P < 0.001) and GLP-1 RA first group (P < 0.001) by week 24
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, parallel trial, participants with poorly controlled type 2 diabetes were recruited and randomized to receive once-daily insulin therapy, degludec (Insulin-GLP-1 RA relay group, mean 16.8 ± 11.4 IU/day), for 12 weeks and then liraglutide for 12 weeks or subcutaneous injections of GL…
Report a problemFND-3503442801
02HumanRandomized controlled trialEfficacy outcome
In adults with poorly controlled type 2 diabetes, liraglutide given first lowered HbA1c significantly by week 24.
In plain wordsIn adults with poorly controlled type 2 diabetes, liraglutide lowered HbA1c by week 24.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change by week 24 (liraglutide first group)
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.9 mg · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
The levels of fasting plasma glucose and HbA1c significantly decreased in the Insulin-GLP-1 RA relay group (P < 0.001) and GLP-1 RA first group (P < 0.001) by week 24
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, parallel trial, participants with poorly controlled type 2 diabetes were recruited and randomized to receive once-daily insulin therapy, degludec (Insulin-GLP-1 RA relay group, mean 16.8 ± 11.4 IU/day), for 12 weeks and then liraglutide for 12 weeks or subcutaneous injections of GL…
Report a problemFND-3503442802

Studies that did not test the peptide alone7

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with poorly controlled type 2 diabetes, a relay of degludec then liraglutide lowered fasting plasma glucose significantly by week 24.
In plain wordsIn adults with poorly controlled type 2 diabetes, insulin followed by liraglutide lowered fasting blood glucose by week 24.
Peptide
Liraglutide
Outcome
DecreaseFasting plasma glucose change by week 24 (insulin-then-liraglutide relay group)
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The levels of fasting plasma glucose and HbA1c significantly decreased in the Insulin-GLP-1 RA relay group (P < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, parallel trial, participants with poorly controlled type 2 diabetes were recruited and randomized to receive once-daily insulin therapy, degludec (Insulin-GLP-1 RA relay group, mean 16.8 ± 11.4 IU/day), for 12 weeks and then liraglutide for 12 weeks or subcutaneous injections of GL…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3503442803
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with poorly controlled type 2 diabetes, a relay of degludec then liraglutide lowered HbA1c significantly by week 24.
In plain wordsIn adults with poorly controlled type 2 diabetes, insulin followed by liraglutide lowered HbA1c by week 24.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change by week 24 (insulin-then-liraglutide relay group)
Study
n: not reported in source
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The levels of fasting plasma glucose and HbA1c significantly decreased in the Insulin-GLP-1 RA relay group (P < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, parallel trial, participants with poorly controlled type 2 diabetes were recruited and randomized to receive once-daily insulin therapy, degludec (Insulin-GLP-1 RA relay group, mean 16.8 ± 11.4 IU/day), for 12 weeks and then liraglutide for 12 weeks or subcutaneous injections of GL…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3503442804
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with poorly controlled type 2 diabetes, fasting plasma glucose did not differ between the insulin-then-liraglutide relay group and the liraglutide-first group at week 24.
In plain wordsIn adults with poorly controlled type 2 diabetes, fasting glucose did not differ between insulin-then-liraglutide and liraglutide-first groups.
Peptide
Liraglutide
Outcome
No significant changeFasting plasma glucose, relay versus liraglutide first, week 24
Study
n: not reported in source
Comparator
Liraglutide first group
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
although no intergroup differences were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, parallel trial, participants with poorly controlled type 2 diabetes were recruited and randomized to receive once-daily insulin therapy, degludec (Insulin-GLP-1 RA relay group, mean 16.8 ± 11.4 IU/day), for 12 weeks and then liraglutide for 12 weeks or subcutaneous injections of GL…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3503442805
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with poorly controlled type 2 diabetes, HbA1c did not differ between the insulin-then-liraglutide relay group and the liraglutide-first group at week 24.
In plain wordsIn adults with poorly controlled type 2 diabetes, HbA1c did not differ between insulin-then-liraglutide and liraglutide-first groups.
Peptide
Liraglutide
Outcome
No significant changeHbA1c, relay versus liraglutide first, week 24
Study
n: not reported in source
Comparator
Liraglutide first group
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
although no intergroup differences were observed.
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, parallel trial, participants with poorly controlled type 2 diabetes were recruited and randomized to receive once-daily insulin therapy, degludec (Insulin-GLP-1 RA relay group, mean 16.8 ± 11.4 IU/day), for 12 weeks and then liraglutide for 12 weeks or subcutaneous injections of GL…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3503442806
07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In participants in the lowest C-peptide quartile, the HbA1c reduction tended to be larger with the insulin-then-liraglutide relay than with liraglutide first, without reaching significance (P = 0.072).
In plain wordsIn people with the lowest C-peptide, HbA1c fell somewhat more with insulin then liraglutide than with liraglutide first, but this was not statistically significant.
Peptide
Liraglutide
Outcome
No significant changeHbA1c reduction in the lowest C-peptide quartile, relay versus liraglutide first
Study
n: not reported in source
Comparator
Liraglutide first group
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
The reduction of HbA1c in the Insulin-GLP-1 RA relay group tended to be larger than that in the GLP-1 RA first group in the lowest CPR (C-peptide immunoreactivity) quartile (P = 0.072).
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, parallel trial, participants with poorly controlled type 2 diabetes were recruited and randomized to receive once-daily insulin therapy, degludec (Insulin-GLP-1 RA relay group, mean 16.8 ± 11.4 IU/day), for 12 weeks and then liraglutide for 12 weeks or subcutaneous injections of GL…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3503442807
08HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with poorly controlled type 2 diabetes, adverse events in the trial, which covered insulin and liraglutide regimens, were mostly gastrointestinal problems.
In plain wordsIn adults with poorly controlled type 2 diabetes, most side effects in the trial were stomach and gut problems.
Peptide
Liraglutide
Outcome
Not applicableGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
The adverse events consisted of gastrointestinal problems, followed by hypoglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, parallel trial, participants with poorly controlled type 2 diabetes were recruited and randomized to receive once-daily insulin therapy, degludec (Insulin-GLP-1 RA relay group, mean 16.8 ± 11.4 IU/day), for 12 weeks and then liraglutide for 12 weeks or subcutaneous injections of GL…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3503442808
09HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with poorly controlled type 2 diabetes, hypoglycemia was the next most common adverse event type in the trial, which covered insulin and liraglutide regimens.
In plain wordsIn adults with poorly controlled type 2 diabetes, low blood sugar was the second most common side effect in the trial.
Peptide
Liraglutide
Outcome
Not applicableHypoglycemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
The adverse events consisted of gastrointestinal problems, followed by hypoglycemia.
1 context sentence(design, population, supporting numbers)
Summary · context
In an open-label, parallel trial, participants with poorly controlled type 2 diabetes were recruited and randomized to receive once-daily insulin therapy, degludec (Insulin-GLP-1 RA relay group, mean 16.8 ± 11.4 IU/day), for 12 weeks and then liraglutide for 12 weeks or subcutaneous injections of GL…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3503442809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.